Abstract
The severity of COVID-19 has resulted in a global rush to find the right antiviral treatment to conquer the pandemic and to treat patients. This requires reliable studies to support treatment. In a recently published study by Gautret et al. the authors concluded that hydroxychloroquine monotherapy and hydroxychloroquine in combination with azithromycin reduced viral load. However, this trial has several major methodological issues, including the design, outcome measure and the statistical analyses. In this paper we discuss the background, clinical evidence, pharmacology and methodological issues related to this clinical trial. We understand the rush to release results, however in case conclusions are far reaching the evidence needs to be robust.
Citations
Aug 7, 2020·American Journal of Physiology. Lung Cellular and Molecular Physiology·Sue C Bodine, Rory E Morty
Jul 29, 2020·International Journal of Molecular Sciences·Rami A Al-HoraniKholoud F Aliter
Nov 3, 2020·American Journal of Therapeutics·Cosima RughinişSorina Vasile
Dec 30, 2020·The American Journal of Bioethics : AJOB·Alex John London
Dec 31, 2020·Pharmacology Research & Perspectives·Camilla Servidio, Francesco Stellacci
Jan 20, 2021·Pulmonary Pharmacology & Therapeutics·Juan Ignacio Morán BlancoKarina Villar Gómez de Las Heras
Aug 30, 2020·American Journal of Epidemiology·Matthew P FoxEleanor J Murray
Feb 25, 2021·The Cochrane Database of Systematic Reviews·Bhagteshwar SinghTom Fletcher
Apr 16, 2021·ACS Pharmacology & Translational Science·Tessa M FirestoneCaroline L Ng
Apr 22, 2021·Science & Education·Cristiano B MouraNathan Willig Lima
Apr 29, 2021·Journal of Pharmacy Practice·Rana Aljadeed
Jun 7, 2021·BMC Medical Research Methodology·Lonni BesançonClémence Leyrat
Jul 6, 2021·Frontiers in Pharmacology·Safaet AlamIsa Naina Mohamed
Jul 11, 2021·Pharmacoepidemiology and Drug Safety·Salka EnnersMartin Schulz